Andrew Pusar, a partner in Goodwin’s Technology Companies and Life Sciences group, concentrates in general corporate and securities law and has significant experience in capital markets transactions, mergers and acquisitions, venture capital financings, SEC compliance and corporate governance. Andrew represents public and private emerging growth technology and life science companies as well as venture capital funds and investment banks focusing on technology and life science companies. He has experience advising companies through every stage of the corporate life cycle – from initial financing through successful initial public offering or acquisition.
Representative Matters
Andrew’s representative company clients include: Toast, Olo, Phreesia, Sema4, Found Health, Goldbelly, Suno, Updater, CareSyntax, Arena Technologies, Sesame, Solvely, Ovax, Truehold, Distyl, Jobber, Propel, Jump, Toggle, Mindset Care, Pawlicy, Allen Control System, Commerce Layer, Priori Legal, Interactions, SourcePoint, ViralGains, Duffel, Pair Eyewear, Open Evidence, Two Front, Hashboard, Agora Brands, Welleum, April Tax, Cloudframe, Elysium Health, and Halsbrook, among others.
Has represented numerous venture capital firms in early stage seed financings through late stage growth equity financings. Such firms include Benchmark, Felicis, Greycroft, Lightspeed, Redpoint, and Archerman Capital, among others
Jobber in its Series D financing led by General Atlantic
Sesame in its Series B financing led by GV
CareSyntax in its Series C financing led by PFM, Intel and Blackrock
Atom Finance in its Series B financing led by SoftBank
Commerce Layer in its Series B financing led by Coatue and Benchmark
Goldbelly in its Series C financing led by Spectrum Equity and Intel Capital
Maximus in its joint venture with IMAX Corporation
Toast in its Series F financing with participation by Bessemer Venture Partners, TPG, Greenoaks Capital and Tiger Global Management.
SmileDirectClub in its preferred equity financing with participation from Clayton, Dubilier & Rice, Kleiner Perkins and Spark Capital
Kensho Technologies in its Series B financing with participation by S&P, Goldman Sachs, General Catalyst, Morgan Stanley and JPMorgan
Codiak BioSciences in its Series C financing with participation by ARCH Venture Partners, Flagship Pioneering and Fidelity Management and Research Company
Glossier in its Series B financing led by Institutional Venture Partners, with participation from Index Ventures, Thrive Capital and Forerunner Ventures
Anchor FM in its Series A financing led by Google Ventures and Accel
Precision Biologics in its Series A financing by an affiliate of NantWorks
Orchard Platform in its Series B financing led by Thrive Capital, Spark Capital and Canaan Partners
Even Financial in its Series A financing with participation by GreatPoint Ventures, Goldman Sachs PSI, Canaan Partners, Fidelity, Lerer Hippeau and AMEX
EasyKnock in its acquisition of Ribbon
Even Financial in its sale to MoneyLion
Pond5 in its sale to ShutterStock
Bbot in its sale to DoorDash
The Infatuation in its sale to JPMorgan Chase
Phreesia in its acquisition of Insignia Health/li>
Updater in its acquisition of Dolly
Amper Music in its sale to Shutterstock
StellaService in its acquisition by Medallia
Even Financial in its acquisition of LeapLife
MediaMorph in its sale to Whip Media Group
Anchor FM in its sale to Spotify
7Park Data in its sale to Vista Equity Partners
Kensho Technologies in its sale to S&P Global
Interactions in its acquisition of Digital Roots
Orchard Platform in its sale of substantially all of its assets to Kabbage, Inc.
Nalari Health in its sale to BehaveCare
Catheter Connections in its sale to Merit Medical Systems
Toast, Inc. in its initial public offering
Phreesia, Inc. in its initial public offering and its primary and secondary follow-on offerings
CRISPR Therapeutics AG in its initial public offering
Represented the underwriters in Olo’s initial public offering
Represented the underwriters, including RBC, in Altair Engineering’s initial public offering and follow-on offering
Represented investment bankers, including Cowen, in G1 Therapeutics’ initial public offering and follow-on offering
Represented William Blair in follow-on offerings by USA Technologies
Represented Cowen in follow-on offerings by Albireo Pharma
Represented the underwriter in Oncobiologics’ initial public offering
Represented the underwriters in a follow-on offering by Syndax Pharmaceuticals
Represented Cowen and Company in multiple “At-the-Market” transactions
Andrew is a frequent lecturer at Columbia Business School, Columbia Law School and Cornell Tech on venture financings and other elements of start-up law. He also holds office hours for emerging companies working with the New York Angels, which is one of the longest-running active angel groups in New York City. Andrew is also an active leader at Goodwin, committed to global initiatives supporting practice management, and associate development efforts rooted in the firm’s core values. He frequently participates in Goodwin’s recruiting, training and mentoring efforts which focus on the importance of opportunity, inclusion, and belonging for all.
Professional Experience
Prior to joining Goodwin, Andrew was an associate in the New York office of Davis Polk & Wardwell LLP.
Credentials
Education
JD2012
Columbia Law School
(Harlan Fiske Stone scholar)
BA2009
Harvard University
Admissions
Bars
New York
New Jersey
Recognition & Awards
Andrew has been recognized by The Best Lawyers as a Best Lawyers: Ones to Watch in America™ for his work in Corporate Law 2022-2024.
